To the Editor:

The severe acute respiratory syndrome-coronarovirus 2 pandemics overwhelmed the critical care units (CCUs) in Alsace, France. The disease evokes acute respiratory distress syndrome (ARDS) ([@R1]). Therefore, as much as \~20 patients *per diem* (d) presented in the emergency department (ED) of the Mulhouse Hospital ("Centre Hospitalier de Mulhouse" \[CHM\]) requiring endotracheal intubation (intubation) and controlled mechanical ventilation (CMV). To off-load the CCU of the CHM, a modular army field hospital ("Element Militaire de Réanimation": EMR, i.e. tents) was set up mid-March 2020. A sympatholytic, alpha-2 agonist, clonidine (Catapres, Catapressan; Boehringer Ingelheim, Paris, France) with sedative effects ([@R2], [@R3]) was used for cooperative sedation. This cheap, widely available drug does not depress the respiratory generator ([@R4]), shortens the duration of CMV (5) and the CCU length of stay (LOS) ([@R6]). We report on the sedation and ventilation method.

The patients (18--70 yr old, body mass index \< 37, *n* = 47) presented with little comorbidities, positive testing to coronarovirus-2, ARDS, and no other organ failure: (1) patients transferred from the CCU of the CHM under conventional sedation (midazolam + sufentanil or propofol + sufentanil) for weaning and (2) moderate or severe ARDS (Pa[o]{.smallcaps}~2~/F[io]{.smallcaps}~2~ = P/F \< 200 or 100, respectively) patients after intubation, conventional sedation, and paralysis and transferred directly from the ED to the EMR. Some mild ARDS deteriorated to severe ARDS after admission to the EMR. Our method is described in the last subset of patients. They present with a high neural drive, hyperthermia (38--40°C), and inflammation restricted to the lung ([@R7]) (*pulmonary* ARDS with a low prevalence of circulatory failure). This evokes patient's self-inflicted lung injury (P-SILI; tachypnea: increased respiratory rate \[RR\]; hyperpnea: increased tidal volume: \[Vt\]) requiring CMV ([@R8]) to avoid inflammation evoked by the spontaneous breathing (SB) itself (P-SILI), in addition to the inflammation evoked by the virus and ventilator-induced lung injury.

Given previous experiences ([@R9]--[@R12]), austere conditions, and the massive influx of patients, the priorities were as follows: 1) a high turn-over requiring early SB. Many patients could not be admitted to the CHM and were dispatched elsewhere; 2) simplicity: at odd with other's practice, no specialized prone positioning team was available; and 3) anesthetics shortage. Upon admission, after "normalized" volemia (iterative passive leg raising under echocardiographies) and absence of contraindications (sick sinus syndrome, atrio-ventricular block II/III, acute kidney injury), conventional sedation is switched to clonidine 1--2 μg/kg/hr (∼23 vials/70 kg, i.e., up to 3,360 μg/d; --2 \< Richmond Agitation-Sedation Scale \[RASS\] \< 0). Rescue sedation (midazolam 3--5 mg IV as required) addresses the slow onset of sedation evoked by clonidine (3--4 hr) administered "without" loading dose to --2 \< RASS \< 0. Clonidine sedation is supplemented with haloperidol (up to 5 mg × 4) "if" needed. "More" importantly, increased RR and Vt are addressed: 1) iterative echocardiographies optimize the cardiac output (CO) and suppress systemic acidosis ([@R13]); 2) the normalized CO, and the sympatholysis evoked by clonidine, improve the microcirculation, as documented by iterative arterial and venous gases, diuresis, etc; and 3) temperature is normalized to ∼35°C to lower oxygen consumption (V[o]{.smallcaps}~2~). Given the sub-zero °C temperature observed in Alsace, March 2020, and despite massive warming under the tents, the weather may have helped normalizing V[o]{.smallcaps}~2~, (4) clonidine suppresses agitation, pain, and a high neural drive. SB with mild permissive hypercapnia (40--50 mm Hg) is actively pursued "as soon as the factors of P-SILI are addressed" (above). As soon as SB is set, proning sequences are switched to the continuous "upright" position ([@R14]). Low level pressure support (PS) addresses the work of breathing caused by the circuit, valves, and endotracheal tube. As soon as SB is achieved, the positive end-expiratory pressure (PEEP) is easily reset to higher levels (plateau pressure ≤30 cm H~2~O). Under SB, high PEEP allows one to achieve high arterial oxygen saturation greater than 96% and suppresses the hypoxic drive and tachypnea. The F[io]{.smallcaps}~2~ is lowered from 1 to 0.4 within 12--72 hour. Then, given a steady F[io]{.smallcaps}~2~ equals to 0.4, PEEP is lowered to ∼10 cm H~2~O within an additional 12--72 hour. Under clonidine infusion (--2 \< RASS \< 0), extubation of the trachea allows weaning. This method (cooperative sedation with clonidine, immediate P-SILI control, early SB-low PS-high PEEP, upright position) was used earlier ([@R9], [@R10], [@R12], [@R13]).

The absence of detailed results (length of intubation, CMV, SB, P/F, inflammatory markers, etc.) relates to the spartan conditions, minimal staffing with a priority to patients' care, without retrospective access to the "contaminated" files. Obviously, the observations need documentation: 1) easy implementation of CMV or SB (CMV: no major hypercapnia; SB: no tachypnea, hyperpnea, hypercapnia, high neural drive, inadvertent extubation, absence of agitation); 2) at variance with ([@R15], [@R16]), extubation of a clinically significant number of patients transferred directly from the ED to the EMR was achieved within ∼2--10 d; and 3) massive anesthetic sparing. Iterative checking of volemia and absence of administration of opiates led to little hypotension/bradycardia.

Finally, 1) the low mortality (*n* = 47, ∼8.5%; **Table [1](#T1){ref-type="table"}**) does not compare with the mortality observed in young patients elsewhere (Seattle: 37% \[[@R17]\]; Wuhan: 38% \[[@R18]\]; New York: 76% \[[@R19]\]): our cohort is biased toward young patients with little comorbidities and single-organ failure (median: 62 yr old; range: 54--67); 2) dexmedetomidine presents advantages (U.S. Food and Drug Administration approval, IV preparation, shorter time to steady state cooperative sedation, no contraindication in the setting of acute kidney injury); and 3) patient's care was designed mid-March 2020, that is, before a switch emphasizing noninvasive ventilation.
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